Chapter

Challenges and Opportunities for Respiratory Syncytial Virus Vaccines

Volume 372 of the series Current Topics in Microbiology and Immunology pp 259-284

Date:

Live-Attenuated Respiratory Syncytial Virus Vaccines

  • Ruth A. KarronAffiliated withCenter for Immunization Research, Department of International Health, Bloomberg School of Public Health, Johns Hopkins University Email author 
  • , Ursula J. BuchholzAffiliated withLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health
  • , Peter L. CollinsAffiliated withLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.